Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.54 is 95% below its 5-year average of 30.23, near the low end of its 5-year range (1.06–81.86).
As of the fiscal period ended Tuesday, June 30, 2026. 12.53% below its 12-month average of 1.76.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.54.
QUICK RATIO (ACID-TEST)
1.54
QUICK RATIO (ACID-TEST) AVG TTM
1.76
QUICK RATIO (ACID-TEST) AVG 3Y
7.85
QUICK RATIO (ACID-TEST) AVG 5Y
30.23
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-12.53%
CURRENT VS 3Y AVG
-80.37%
CURRENT VS 5Y AVG
-94.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.28
median of 795 covered companies
CURRENT VS SECTOR MEDIAN
-53.01%
vs the sector median at left
Greenwich LifeSciences, Inc.
Market Cap
$243.66M
Quick Ratio (Acid-Test)
1.54
TTM Avg
1.76
3Y Avg
7.85
5Y Avg
30.23
Market Cap
$242.50M
Quick Ratio (Acid-Test)
2.69
TTM Avg
2.01
3Y Avg
1.61
5Y Avg
1.29
Market Cap
$240.38M
Quick Ratio (Acid-Test)
0.10
TTM Avg
1.46
3Y Avg
1.56
5Y Avg
2.73
Market Cap
$240.70M
Quick Ratio (Acid-Test)
10.14
TTM Avg
15.36
3Y Avg
19.42
5Y Avg
27.25
Market Cap
$242.28M
Quick Ratio (Acid-Test)
20.30
TTM Avg
4.91
3Y Avg
4.89
5Y Avg
6.73
Market Cap
$236.60M
Quick Ratio (Acid-Test)
5.86
TTM Avg
4.06
3Y Avg
6.91
5Y Avg
7.76
Market Cap
$240.34M
Quick Ratio (Acid-Test)
4.70
TTM Avg
7.13
3Y Avg
7.51
5Y Avg
5.59
Market Cap
$246.31M
Quick Ratio (Acid-Test)
9.97
TTM Avg
9.63
3Y Avg
16.17
5Y Avg
19.97
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $243.66M | 1.54 | 1.76 | 7.85 | 30.23 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | 2.69 | 2.01 | 1.61 | 1.29 |
| Galectin Therapeutics Inc. (GALT)vs › | $240.38M | 0.10 | 1.46 | 1.56 | 2.73 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $240.70M | 10.14 | 15.36 | 19.42 | 27.25 |
| Q32 Bio Inc. (QTTB)vs › | $242.28M | 20.30 | 4.91 | 4.89 | 6.73 |
| Invivyd, Inc. (IVVD)vs › | $236.60M | 5.86 | 4.06 | 6.91 | 7.76 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.34M | 4.70 | 7.13 | 7.51 | 5.59 |
| Quantum-Si incorporated (QSI)vs › | $246.31M | 9.97 | 9.63 | 16.17 | 19.97 |
| InflaRx N.V. (IFRX)vs › | $237.88M | 8.22 | 4.35 | 5.50 | 5.94 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.27M | 1.35 | 1.13 | 1.14 | 1.18 |
Quick Ratio
1.54
Excludes inventory
Current Ratio
1.54
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 1.54 |
| 2026-03-31 | 2.01 |
| 2025-12-31 | 1.06 |
| 2025-09-30 | 2.35 |
| 2025-06-30 | 1.85 |
| 2025-03-31 | 1.91 |
| 2024-12-31 | 2.62 |
| 2024-09-30 | 6.91 |
| 2024-06-30 | 5.34 |
| 2024-03-31 | 14.13 |
| 2023-12-31 | 23.74 |
| 2023-09-30 | 30.76 |
| 2023-06-30 | 36.29 |
| 2023-03-31 | 50.56 |
| 2022-12-31 | 51.23 |
| 2022-09-30 | 65.74 |
| 2022-06-30 | 75.01 |
| 2022-03-31 | 81.86 |
| 2021-12-31 | 70.63 |
| 2021-09-30 | 63.51 |
| 2021-06-30 | 45.66 |
| 2021-03-31 | 45.17 |
| 2020-12-31 | 27.41 |
| 2020-09-30 | 3.87 |
| 2020-06-30 | 0.15 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 0.12 |
